Defunct Company
Total Trials
11
As Lead Sponsor
As Collaborator
0
Total Enrollment
822
NCT00253331
Lab Study of MQX-503 in Treatment of Raynaud's
Phase: Phase 2/3
Role: Lead Sponsor
Start: Nov 30, 2004
Completion: Sep 30, 2005
NCT00253305
Topical Gel Anti-Fungal Agent for Tinea Unguium
Phase: Phase 2
Start: Sep 30, 2005
Completion: Not specified
NCT00266669
Phase III Study of Topical Gel for Treatment and Prevention of Raynaud's Phenomenon
Phase: Phase 3
Start: Dec 31, 2005
Completion: May 31, 2006
NCT00378521
Dose Response Study of a Topical Gel for the Treatment of Raynaud's Phenomenon
Start: Jul 31, 2006
Completion: Jul 31, 2006
NCT00419419
Phase III Study of a Topical Gel Formulation for Treatment and Prevention of Raynaud's Phenomenon
Start: Dec 31, 2006
NCT00480753
Dose Response Study of a Topical Formulation of Nitroglycerin for the Treatment of Raynaud's Phenomenon
Start: May 31, 2007
Completion: Aug 31, 2007
NCT00513994
MQX-503 vs Nitroglycerin Ointment: A Pharmacokinetic Comparison in Normal Subjects
Phase: Phase 1
Start: Aug 31, 2007
Completion: Oct 31, 2007
NCT00666354
Dose Response and Safety Study of Topical Methotrexate for the Treatment of Fingernail Psoriasis
Start: Oct 31, 2007
Completion: Jan 31, 2009
NCT00577304
A Study of a Topical Form of Nitroglycerin and Placebo in the Treatment and Prevention of Raynaud's Phenomenon
Start: Dec 31, 2007
Completion: Mar 31, 2008
NCT00841594
MQX-503 Applied to the Hand Versus Nitroglycerin Ointment Applied to the Chest: A Pharmacokinetic Comparison
Start: Feb 28, 2009
Completion: Mar 31, 2009
NCT00934427
Study of a Topical Formulation for the Treatment and Prevention of Raynaud's Phenomenon Symptoms
Start: Jun 30, 2009
Completion: Jul 31, 2010